Neonatal candidiasis: prophylaxis and stewardship

Neonatal candidiasis is uncommon but can cause invasive sepsis with substantial mortality, especially in very preterm infants. Risk rises with extremely low birth weight, central venous catheters, prolonged broad-spectrum antibiotics, abdominal surgery, repeated instrumentation and outbreaks of Candida in a neonatal intensive care unit. The clinical burden includes longer admission, neurodevelopmental complications and difficult decisions about whether treatment can safely stop.

Prophylaxis can reduce fungal infection in some high-risk neonatal populations, yet benefit depends heavily on local case mix, Candida species and resistance patterns. Routine antifungal prophylaxis for every preterm infant is hard to justify; selective use may be more defensible. Fluconazole-related toxicity, drug interactions, liver injury and ecological pressure make governance essential, while oral nystatin should not be mistaken for protection against bloodstream infection.

Antifungal stewardship is the repeated process of selecting the right agent, obtaining reliable microbiological evidence, reassessing need at defined intervals and narrowing or stopping treatment promptly. It includes deciding when prophylaxis is justified, monitoring exposure and adverse effects, and removing infection sources. Prophylaxis cannot replace sterile insertion practices, catheter-care bundles, antibiotic discipline, early recognition of sepsis or rapid transfer to a tertiary neonatal service.

Australian neonatal units operate within national surveillance through the Australian and New Zealand Neonatal Network, state infection-prevention frameworks and hospital antimicrobial stewardship programs. Geography matters: babies may be transferred between Melbourne, Sydney, Perth, Brisbane or regional hospitals, with neonatal teleconferencing supporting round-the-clock advice. Public inpatient medicines usually follow state formularies, while discharge prescriptions may use the PBS. Clear escalation pathways are therefore more useful than informal advice across a “proper run” of weekend cover.

Diagnosis before prophylaxis

Diagnosis starts with blood cultures collected promptly, with adequate volume and, when possible, paired samples from a peripheral site and the central line. Differences in time to positivity may help distinguish true infection from contamination, while species identification and susceptibility testing guide treatment. A positive surface swab alone rarely establishes invasive disease; it should prompt review of clinical signs, sampling technique and the possibility of colonization.

When cultures are negative but clinical suspicion remains high, clinicians may use adjunctive tests. Beta-D-glucan and Candida mannan antigen assays can support a diagnosis in selected settings, yet availability, neonatal specificity and interpretation remain barriers. As prenatal karyotyping methods illustrate for fetal assessment, test choice should follow indication, pre-test explanation and the result that will change care. The same principle supports selective use of non-culture fungal tests.

Weighing prophylaxis against harm

High-risk units need a local prophylaxis policy grounded in incidence, species distribution and outcome data rather than a blanket prescription. Very low birth weight infants with central catheters or prolonged antibiotic exposure may be considered for prophylaxis after neonatal specialist review. Decisions should change during an outbreak or when unit epidemiology shifts, with predefined criteria for starting and stopping treatment.

Fluconazole is the agent most often discussed for neonatal prophylaxis, but its advantages depend on susceptibility and local resistance. Weight and gestational age affect clearance, so trough levels and liver toxicity need attention. Miconazole, nystatin and amphotericin B have different roles and do not provide interchangeable systemic protection. Oral nystatin may address oral thrush but cannot prevent candidemia.

Each protocol should specify eligible infants, agent, dose, duration, monitoring and the clinician who can approve exceptions. Drug interactions, hepatic dysfunction, renal impairment, poor absorption and medication errors belong in the risk assessment, not just the pharmacy appendix. Beyond immediate protocols, broader cultural and historical perspectives can sharpen thinking about infection; the Art and Archaeology archive is one such reading source. Such material does not set neonatal policy, but it can encourage teams to examine assumptions and the wider context of antimicrobial use.

Building an Australian stewardship program

Australian units benefit from shared protocols across metropolitan and regional networks. The value of coordinated fetal, obstetric and neonatal planning is illustrated by fetal macrosomia planning, where delivery decisions depend on surveillance, family communication and neonatal readiness. For candidiasis, a comparable pathway should connect microbiology, pharmacy, infection prevention and the bedside team, with one named clinician responsible for review.

Local protocol and bedside review

Protocol decisions

• Which gestational-age and weight groups are eligible for antifungal prophylaxis after specialist review.
• Preferred agent, dose, renal and hepatic adjustments, monitoring, and start and stop criteria.
• Infection-control thresholds for environmental cultures, cohorting and catheter-care reminders.
• How AusCD and susceptibility results reach the prescriber, pharmacist and family.

At the bedside, the review should be practical rather than ceremonial. In Australian hospitals, teams often talk about sorting out a proper run of treatment, including who owns the next dose and what happens at the weekend. The antimicrobial stewardship pharmacist can check indication, interactions, renal function, monitoring and discharge supply, while infection-prevention staff review line bundles and unit outbreaks.

Bedside prompts

• Could this antimicrobial be stopped today based on cultures and the clinical trajectory?
• Does the baby still need the central line or full-dose treatment?
• Have medication safety, therapeutic drug monitoring and family concerns been reviewed?

Metrics should include invasive Candida incidence, Candida bloodstream infections, central-line days, empirical antifungal days, doses adjusted after therapeutic drug monitoring and documented cessation. A unit can compare these with peer neonatal services without publishing individual patient details. Clear escalation rules for regional transfer and neonatal teleconference advice help maintain continuity.

Treatment, monitoring, and dose safety

For suspected invasive candidiasis, empirical treatment should follow local neonatal infectious-disease and microbiology advice. An echinocandin such as micafungin may be favoured in an unstable or severely ill newborn, while fluconazole may suit a stable infant once susceptibility is known. Amphotericin B deoxycholate can be an alternative in selected circumstances. Choice must reflect Candida species, site, organ function and local resistance.

Neonatal dosing requires frequent weight and gestational-age review because clearance changes quickly during the first weeks. Fluconazole exposure may justify trough testing and liver monitoring; micafungin is often managed with hepatic surveillance and careful volume assessment. Concurrent medicines, concentrated electrolytes and renal dysfunction can alter exposure or safety, so an independent medication check is valuable before prolonged therapy.

Potential future tools include immune-based interventions and engineered products, so clinical teams can monitor biotherapy developments without treating experimental approaches as current prophylaxis. For now, source control remains decisive: assess whether the central line can be removed, investigate abdominal, renal or disseminated infection, and involve neonatal surgery, ophthalmology or cardiology when indicated.

A documented review should define when blood cultures repeat, when imaging is required, when oral or echinocandin step-down is safe and when treatment stops. Ophthalmology assessment may be relevant after candidemia, while repeat cultures and imaging depend on the organism, source and response. Families need an accessible explanation of why treatment is continuing, changing or ending.

Learning across perinatal systems

Neonatal candidiasis sits within a wider perinatal system, not an isolated prescription decision. FAOPS material on alloimmune thrombocytopenia management provides a useful model because fetal medicine, obstetrics, neonatology, laboratory science and family counselling must share evidence and escalation pathways. The same cooperation helps when maternal infection, congenital abnormalities, prematurity or neonatal sepsis overlap.

FAOPS 2020 was cancelled in April 2020 because of the COVID-19 pandemic and international travel difficulties, yet its online archive preserves valuable scientific material. That history reinforces the value of accessible guidelines, transparent authorship and adaptable links for clinicians who cannot attend a physical meeting. It also offers a reminder that international collaboration can support local decisions without replacing them.

Education should include case-based review of culture collection, line-care observations, antifungal dosing, non-culture testing and outbreak response. Unit leaders can pair junior clinicians with pharmacists, microbiologists and infection-prevention specialists, then use short bedside sessions to address recurring errors. Fetal and neonatal teams can also share protocols with obstetric services so that maternal risk, delivery planning and newborn care remain aligned.

Make stewardship the daily standard

A practical goal is not zero antifungal prescribing. It is earlier confirmation, selective prophylaxis, fewer unnecessary empirical days, reliable dosing and timely cessation. Teams can measure progress through Candida incidence, central-line-associated infection, review timeliness and documented outcomes.

Start with one high-risk neonatal unit and one agreed review standard. Map local Candida species, resistance and risk factors; agree who can start prophylaxis; add a mandatory stop date; and involve families in decisions where treatment is prolonged. Publish the pathway through the antimicrobial stewardship program and neonatal governance group.

Make the next neonatal antimicrobial stewardship meeting count: review one case, test one process, assign one owner and record one measurable change. That focused cycle turns evidence into safer care for babies, clearer decisions for clinicians and better communication with Australian families.